Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Multicenter, Phase III Study Assessing the Effect of 1PC111, a Fixed-Dose Combination of Pitavastatin and Ezetimibe, Versus Pitavastatin or Ezetimibe Monotherapy on Lipid Profiles in Patients With Hypercholesterolemia or Mixed Dyslipidemia

Next Previous
X
Search
Trial Profile

A Randomized, Double-blind, Multicenter, Phase III Study Assessing the Effect of 1PC111, a Fixed-Dose Combination of Pitavastatin and Ezetimibe, Versus Pitavastatin or Ezetimibe Monotherapy on Lipid Profiles in Patients With Hypercholesterolemia or Mixed Dyslipidemia

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 30 Aug 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ezetimibe/pitavastatin (Primary) ; Ezetimibe; Pitavastatin
  • Indications Dyslipidaemias; Hypercholesterolaemia
  • Focus Registrational; Therapeutic Use
  • Sponsors Orient Pharma

    • Most Recent Events

    • 24 Aug 2022 Primary endpoint (The efficacy of 1PC111 is superior to pitavastatin and ezetimibe in patients) has been met as per the results published in the Clinical Therapeutics
    • 24 Aug 2022 Results published in the Clinical Therapeutics
    • 17 May 2022 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top